Etoposid Ebewe (Etoposide)
Topoisomerase II inhibitor for the treatment of various cancers
Etoposid Ebewe contains the active substance etoposide, a cytostatic (chemotherapy) drug belonging to the topoisomerase II inhibitor class. It is used in the treatment of several types of cancer in adults and children, including small cell lung cancer, testicular cancer, acute myeloid leukemia, lymphomas, and ovarian cancer. This medicine is given as a slow intravenous infusion under the supervision of a qualified oncologist.
Quick Facts: Etoposid Ebewe
Key Takeaways
- Etoposide is a cytostatic chemotherapy drug that inhibits topoisomerase II, preventing cancer cell division and leading to cell death in rapidly dividing tumors.
- It is used to treat small cell lung cancer, testicular cancer, acute myeloid leukemia (AML), Hodgkin's and non-Hodgkin's lymphoma, ovarian cancer, and gestational trophoblastic disease.
- The drug must always be given as a slow intravenous infusion (30–60 minutes) – rapid injection can cause dangerous drops in blood pressure.
- Regular blood tests are essential during treatment because etoposide can cause severe suppression of bone marrow function, lowering white blood cells, red blood cells, and platelets.
- Both men and women must use effective contraception during treatment and for at least 6 months afterward, as etoposide may harm an unborn child and affect fertility.
What Is Etoposid Ebewe and What Is It Used For?
Etoposid Ebewe belongs to a group of medicines called cytostatic agents (chemotherapy drugs) used to treat cancer. The active substance, etoposide, is a semi-synthetic derivative of podophyllotoxin, originally extracted from the roots of the American mayapple plant (Podophyllum peltatum). Etoposide has been used in oncology since the 1970s and is included on the WHO Model List of Essential Medicines, reflecting its importance in global cancer treatment.
The drug works by inhibiting topoisomerase II, an enzyme that is essential for DNA replication and repair. By blocking this enzyme, etoposide prevents cancer cells from properly unwinding and replicating their DNA, which causes irreversible DNA strand breaks and ultimately leads to apoptosis (programmed cell death). Etoposide is particularly effective against rapidly dividing cells in the late S-phase and G2-phase of the cell cycle, making it cell-cycle specific.
Approved Indications in Adults
Etoposid Ebewe is approved for the treatment of several types of cancer in adults. It is most commonly used as part of combination chemotherapy regimens rather than as a single agent. The approved indications include:
- Testicular cancer: Etoposide combined with cisplatin (EP regimen) is a cornerstone of treatment for non-seminomatous and seminomatous germ cell tumors. This combination achieves cure rates exceeding 80% even in advanced disease, according to European Society for Medical Oncology (ESMO) guidelines.
- Small cell lung cancer (SCLC): The etoposide-platinum combination (EP or EC) is the standard first-line treatment for both limited-stage and extensive-stage SCLC, as recommended by the National Comprehensive Cancer Network (NCCN) and ESMO.
- Acute myeloid leukemia (AML): Etoposide is used in induction and consolidation regimens for AML, often in combination with cytarabine and an anthracycline.
- Hodgkin's lymphoma: Used in salvage chemotherapy regimens such as ICE (ifosfamide, carboplatin, etoposide) or DHAP for relapsed or refractory disease.
- Non-Hodgkin's lymphoma: Part of several combination regimens for aggressive subtypes.
- Gestational trophoblastic neoplasia: Used in EMA-CO and EMA-EP regimens for high-risk gestational trophoblastic disease.
- Ovarian cancer: Oral etoposide may be used for platinum-resistant or recurrent ovarian cancer.
Pediatric Indications
In children, Etoposid Ebewe is used for the treatment of acute myeloid leukemia and lymphomas (both Hodgkin's and non-Hodgkin's). Pediatric dosing is calculated based on body surface area and follows protocols established by pediatric oncology cooperative groups. The safety and efficacy in children have been established through decades of clinical experience and research coordinated by organizations such as the Children's Oncology Group (COG).
Your oncologist will determine the exact reason for prescribing Etoposid Ebewe based on your specific cancer type, stage, and overall health. The drug may also be used for conditions not listed here, as determined by your treating physician in accordance with current evidence-based guidelines.
What Should You Know Before Taking Etoposid Ebewe?
Contraindications
Etoposid Ebewe must not be used in the following situations:
- Allergy to etoposide or any of the excipients in the formulation, including benzyl alcohol, ethanol, citric acid, macrogol 300, or polysorbate 80.
- Recent live vaccination: You must not receive etoposide if you have recently been vaccinated with a live vaccine, including yellow fever vaccine. Live vaccines are contraindicated during chemotherapy because the suppressed immune system may lead to disseminated vaccine infection.
- Breastfeeding: Etoposide is excreted in breast milk and can harm a nursing infant. Breastfeeding must be discontinued before treatment begins.
Etoposide must only be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapy. Adequate diagnostic and treatment facilities must be readily available for the management of therapy-related complications, including severe myelosuppression and anaphylactic reactions.
Warnings and Precautions
Before you receive Etoposid Ebewe, inform your doctor, pharmacist, or nurse about the following conditions, as dose adjustments or additional monitoring may be required:
- Active infections: Etoposide suppresses the immune system, which can make existing infections worse. Any active infection should ideally be treated before starting chemotherapy.
- Recent radiation therapy or chemotherapy: Prior treatments may have depleted your bone marrow reserves, increasing the risk of severe myelosuppression with etoposide.
- Low serum albumin: Etoposide is highly protein-bound (approximately 97%). Low albumin levels result in higher concentrations of free (unbound) etoposide in the blood, which increases both the drug's efficacy and toxicity. Dose adjustments may be necessary.
- Liver impairment: Etoposide is primarily metabolized by the liver. Impaired hepatic function can lead to increased drug exposure and higher risk of adverse effects. Liver function tests should be monitored regularly.
- Kidney impairment: Approximately 30–40% of etoposide is excreted unchanged by the kidneys. Reduced kidney function requires dose adjustment based on creatinine clearance to prevent drug accumulation and toxicity.
Tumor Lysis Syndrome
Effective cancer treatment can rapidly destroy large numbers of cancer cells. In rare cases, this causes tumor lysis syndrome (TLS), a potentially life-threatening condition where harmful substances released from dying cancer cells enter the bloodstream. TLS can cause severe damage to the kidneys, heart, and liver, and may be fatal if not promptly treated. Your oncologist will monitor your blood chemistry closely and may prescribe preventive measures such as hydration and allopurinol before starting etoposide in patients at high risk for TLS.
Bone Marrow Suppression
Etoposide is a potent myelosuppressive agent. It can significantly reduce the production of blood cells in the bone marrow, leading to:
- Leukopenia/neutropenia (low white blood cells) – increasing infection risk
- Thrombocytopenia (low platelets) – increasing bleeding risk
- Anemia (low red blood cells) – causing fatigue and weakness
The nadir (lowest blood cell count) typically occurs 7–14 days after administration, with recovery usually by day 20–21. Complete blood counts will be performed before each treatment cycle, and treatment may be delayed or doses reduced if counts are too low. The European Medicines Agency (EMA) recommends that treatment should not begin unless the neutrophil count and platelet count are at adequate levels.
Pregnancy and Breastfeeding
Etoposide must not be used during pregnancy unless the treating oncologist determines that the potential benefit to the mother outweighs the risks to the fetus. Animal studies have shown that etoposide is teratogenic and embryotoxic, meaning it can cause birth defects and harm the developing baby.
Contraception requirements: Both male and female patients of reproductive potential must use effective contraception (such as barrier methods or condoms) during treatment and for at least 6 months after the last dose. Men should not father a child during this period.
Fertility: Etoposide may cause temporary or permanent infertility in both men and women. Male patients are strongly advised to seek sperm cryopreservation (sperm banking) counseling before starting treatment. Female patients should discuss fertility preservation options, such as egg or embryo freezing, with their reproductive medicine specialist before beginning chemotherapy.
Breastfeeding: Breastfeeding is strictly contraindicated during etoposide treatment. It is unknown exactly how much etoposide passes into breast milk, but given the drug's cytotoxic mechanism, any exposure poses a significant risk to the nursing infant.
Driving and Operating Machinery
The effects of etoposide on the ability to drive and use machines have not been formally studied. However, since etoposide may cause side effects such as fatigue, nausea, dizziness, or drowsiness, you should not drive or operate machinery if you experience any of these symptoms. Discuss with your oncologist when it is safe to resume these activities.
Etoposid Ebewe concentrate for infusion contains ethanol (alcohol) – 261 mg per ml (26.1% w/v). This amount may be relevant for patients with liver disease, epilepsy, or alcohol dependence. The product also contains benzyl alcohol (20 mg per ml), which can cause allergic reactions and has been associated with serious side effects, including respiratory distress ("gasping syndrome"), in neonates. This product must not be given to premature babies or neonates up to 4 weeks of age unless specifically prescribed by a physician.
How Does Etoposid Ebewe Interact with Other Drugs?
Drug interactions with etoposide can alter its blood levels, increase toxicity, or reduce effectiveness. Because etoposide is primarily metabolized by the liver (via CYP3A4 enzymes) and is highly protein-bound, many potential interactions exist. Your oncologist and pharmacist will carefully review all your medications before each treatment cycle.
Major Interactions
| Drug | Type | Effect | Clinical Action |
|---|---|---|---|
| Ciclosporin | Increased toxicity | Ciclosporin decreases etoposide clearance by up to 50%, significantly increasing exposure and risk of bone marrow suppression | Reduce etoposide dose; close monitoring of blood counts required |
| Cisplatin | Altered clearance | Prior cisplatin administration may reduce etoposide clearance, increasing drug levels and myelosuppressive effects | Adjust dosing sequence and monitor closely |
| Phenytoin / Anticonvulsants | Reduced efficacy | CYP3A4 enzyme-inducing anticonvulsants accelerate etoposide metabolism, potentially reducing its antitumor activity | Consider alternative anticonvulsants; may need higher etoposide dose |
| Warfarin | Increased bleeding risk | Etoposide may enhance the anticoagulant effect of warfarin through protein-binding displacement and hepatic effects | Monitor INR frequently; adjust warfarin dose as needed |
| Live vaccines | Contraindicated | Risk of disseminated vaccine infection due to immunosuppression; includes yellow fever, MMR, varicella, oral polio vaccines | Avoid all live vaccines during and after treatment until immune recovery confirmed |
Additional Interactions
The following additional interactions should be noted:
- Phenylbutazone, sodium salicylate, and acetylsalicylic acid (aspirin): These drugs can displace etoposide from plasma protein binding sites, increasing the concentration of free (active) drug in the blood and potentially enhancing both therapeutic effects and toxicity.
- Anthracyclines (e.g., doxorubicin, epirubicin): Combined use with etoposide may increase the risk of cardiotoxicity and myelosuppression. Cardiac function should be monitored when these drugs are used together.
- Other myelosuppressive agents: Concomitant use with other chemotherapy drugs that suppress bone marrow function increases the risk of severe cytopenias. Dose adjustments may be required based on the specific regimen used.
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): May increase etoposide plasma levels by inhibiting its hepatic metabolism.
- CYP3A4 inducers (e.g., rifampicin, St. John's Wort): May decrease etoposide plasma levels, potentially reducing efficacy.
Always inform your treatment team about all prescription and over-the-counter medications, herbal supplements, vitamins, and dietary supplements you are taking before each treatment cycle.
What Is the Correct Dosage of Etoposid Ebewe?
Etoposid Ebewe dosing is individualized based on body surface area (BSA), the type of cancer being treated, the specific combination regimen, and the patient's overall health, kidney function, and bone marrow status. Your oncologist calculates the exact dose for each treatment cycle.
Adults
Standard IV Dosing Regimens
Regimen A: 50 to 100 mg/m² body surface area administered intravenously daily on days 1 through 5 of a treatment cycle.
Regimen B: 100 to 120 mg/m² body surface area administered intravenously on days 1, 3, and 5 of a treatment cycle.
Treatment cycles are typically repeated every 21 to 28 days, but no sooner than 21 days after the first dose, and only after adequate recovery of blood counts has been confirmed.
| Patient Group | Dose | Schedule | Notes |
|---|---|---|---|
| Adults (standard) | 50–100 mg/m²/day | Days 1–5, repeat q21–28d | Adjust based on combination regimen |
| Adults (alternate) | 100–120 mg/m²/day | Days 1, 3, 5, repeat q21–28d | Minimum 21-day interval between cycles |
| Children | 75–150 mg/m²/day | 2–5 days per cycle | Per local pediatric oncology protocols |
| Renal impairment (CrCl 15–50 ml/min) | 75% of standard dose | Per standard schedule | Further reduction if CrCl <15 ml/min or on dialysis |
| Elderly (>65 years) | Standard dose | Per standard schedule | Adjust based on renal function, not age alone |
Children
In pediatric patients, etoposide is used at doses of 75 to 150 mg/m²/day for 2 to 5 days, depending on the specific treatment protocol. Pediatric dosing is always determined by the treating pediatric oncologist according to established cooperative group protocols (e.g., Children's Oncology Group, SIOP). Etoposide is used in combination with other chemotherapy agents for the treatment of acute myeloid leukemia and lymphomas in children.
Elderly Patients
No specific dose adjustment is required solely on the basis of age. However, elderly patients often have reduced kidney function, and dose adjustments should be made based on measured creatinine clearance. Elderly patients may also have decreased bone marrow reserve, requiring more careful monitoring of blood counts during treatment.
Renal Dose Adjustment
For patients with impaired kidney function, the initial dose should be adjusted based on measured creatinine clearance (CrCl):
- CrCl >50 ml/min: 100% of the standard dose
- CrCl 15–50 ml/min: 75% of the standard dose
- CrCl <15 ml/min or dialysis: Further dose reduction should be considered; consult prescribing guidelines
Subsequent doses should be adjusted based on patient tolerance and clinical response.
Administration
Etoposid Ebewe must NEVER be given as a rapid intravenous injection. It must always be administered as a slow intravenous infusion over at least 30 to 60 minutes. Rapid injection can cause severe and potentially fatal hypotension (dangerously low blood pressure).
The concentrate must be diluted before administration. It should only be diluted with isotonic sodium chloride solution (0.9% NaCl) or isotonic glucose solution (5% dextrose). The final concentration of etoposide in the infusion should not exceed 0.4 mg/ml to prevent precipitation of the drug. Care must be taken to avoid extravasation (leaking of the infusion into surrounding tissue), as this can cause local tissue damage.
Overdose
Since Etoposid Ebewe is administered by healthcare professionals in a controlled clinical setting, overdose is unlikely. However, if an accidental overdose occurs, the primary expected toxicity is severe myelosuppression (bone marrow failure). There is no specific antidote for etoposide overdose. Treatment is supportive and includes blood transfusions, growth factor support (G-CSF), infection prophylaxis, and intensive monitoring. The patient should be transferred to a unit with appropriate hematological support.
What Are the Side Effects of Etoposid Ebewe?
Like all chemotherapy drugs, etoposide can cause side effects, although not everyone will experience them. The type and severity of side effects depend on the dose, duration of treatment, and whether etoposide is given alone or in combination with other drugs. Your oncology team will monitor you closely and provide supportive medications to manage many of these effects.
Tell your doctor or nurse immediately if you experience any of the following: swollen tongue or throat, difficulty breathing, rapid heartbeat, widespread skin redness or rash. These may be signs of a severe allergic reaction (anaphylaxis) that requires emergency treatment.
Very Common Side Effects
May affect more than 1 in 10 patients
- Myelosuppression (bone marrow suppression) – low white blood cells, red blood cells, and platelets (this is why regular blood tests are essential between treatment cycles)
- Nausea and vomiting – anti-emetic medications are routinely prescribed to reduce these effects
- Decreased appetite – nutritional support may be offered
- Constipation
- Temporary hair loss (alopecia) – hair typically regrows after treatment ends
- Liver damage – elevated liver enzymes, elevated bilirubin (jaundice)
- Skin pigmentation changes
- Fatigue (asthenia) and general malaise
- Abdominal pain
Common Side Effects
May affect up to 1 in 10 patients
- Acute leukemia – secondary malignancy, typically acute myeloid leukemia (a known risk with topoisomerase II inhibitors)
- Diarrhea
- Infusion site reactions – pain, swelling, or inflammation at the injection site
- Cardiac arrhythmia (irregular heartbeat) or myocardial infarction (heart attack)
- Severe allergic reactions – including anaphylaxis with bronchospasm
- Dizziness
- Hypotension (low blood pressure) or hypertension (high blood pressure)
- Mucositis – sore lips, mouth ulcers, or throat sores
- Skin reactions – itching (pruritus) or rash
- Phlebitis (inflammation of a vein)
- Infection – due to immunosuppression
Uncommon Side Effects
May affect up to 1 in 100 patients
- Peripheral neuropathy – tingling, numbness, or loss of sensation in hands and feet
- Hemorrhage (bleeding) – due to low platelet counts
Rare Side Effects
May affect up to 1 in 1,000 patients
- Acid reflux (heartburn)
- Flushing
- Seizures (convulsions)
- Fever
- Somnolence (excessive drowsiness or fatigue)
- Transient cortical blindness – temporary loss of vision (reversible)
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) – severe skin reactions with painful blisters and widespread skin detachment (seek emergency care immediately)
- Radiation recall dermatitis – a sunburn-like rash appearing on skin previously exposed to radiation therapy
- Dysphagia (difficulty swallowing)
- Dysgeusia (taste changes)
- Respiratory problems
Frequency Not Known
Cannot be estimated from available data
- Tumor lysis syndrome – potentially life-threatening metabolic complications from rapid cancer cell destruction
- Angioedema – swelling of the face and tongue
- Infertility – may be temporary or permanent
- Bronchospasm – difficulty breathing due to airway constriction
Secondary Leukemia Risk
A clinically important concern with etoposide therapy is the risk of treatment-related acute myeloid leukemia (t-AML), also called secondary leukemia. This is a recognized class effect of topoisomerase II inhibitors. The risk is dose-dependent and increases with cumulative exposure. Secondary leukemia typically develops 2–3 years after etoposide treatment and is characterized by specific chromosomal translocations involving the MLL gene at chromosome 11q23. The estimated cumulative risk ranges from 0.7% to 2.0%, though this varies depending on the regimen used. Your oncologist weighs this long-term risk against the immediate benefit of cancer treatment when designing your chemotherapy plan.
If you experience any side effects, including those not listed here, talk to your doctor, pharmacist, or nurse. You can also report suspected adverse reactions directly to your national pharmacovigilance authority (e.g., the Medicines and Healthcare products Regulatory Agency [MHRA] in the UK, the FDA MedWatch program in the US, or EudraVigilance in the EU). Reporting helps improve the safety monitoring of medicines.
How Should You Store Etoposid Ebewe?
Etoposid Ebewe is stored, prepared, and administered in a hospital or clinic setting. Patients do not normally handle or store this product themselves. However, the following storage requirements apply:
- Concentrate (unopened): Store at or below 25°C. Keep in the original packaging to protect from light.
- Diluted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature. From a microbiological perspective, the diluted product should be used immediately unless prepared under controlled and validated aseptic conditions, in which case it may be stored for up to 24 hours at 2–8°C.
- Keep out of sight and reach of children.
- Do not use after the expiry date printed on the carton and vial (EXP). The expiry date refers to the last day of that month.
Disposal: Etoposide is a cytotoxic substance and must be disposed of according to local regulations for hazardous pharmaceutical waste. Unused medicine should not be disposed of via household waste or wastewater. Ask your pharmacist about proper disposal of medicines no longer needed.
What Does Etoposid Ebewe Contain?
The active substance is etoposide. Each milliliter of concentrate contains 20 mg of etoposide.
The other ingredients (excipients) in the concentrate for solution for infusion are:
- Benzyl alcohol (20 mg/ml) – preservative; may cause allergic reactions and is associated with "gasping syndrome" in neonates
- Ethanol 96% (261 mg/ml, 26.1% w/v) – co-solvent
- Anhydrous citric acid – pH adjuster
- Macrogol 300 (polyethylene glycol 300) – co-solvent
- Polysorbate 80 – surfactant/emulsifier
Appearance and Pack Sizes
Etoposid Ebewe concentrate for solution for infusion is a clear, pale yellow solution. It is available in the following pack sizes:
- 50 mg/2.5 ml vial
- 100 mg/5 ml vial
- 200 mg/10 ml vial
- 400 mg/20 ml vial
- 1,000 mg/50 ml vial
Individual packs contain 1 vial, while multi-packs contain 5 or 10 vials. Not all pack sizes may be marketed in every country.
Preparation and Dilution
The concentrate must be diluted before use. It should only be diluted with 0.9% sodium chloride solution or 5% glucose solution for infusion. The concentration of the final diluted solution should not exceed 0.4 mg/ml to avoid precipitation. Undiluted concentrate must not be administered.
Etoposid Ebewe must not be mixed with any other medicine in the same infusion. Plastic equipment made from acrylic or ABS polymers may crack when exposed to undiluted concentrate; this effect does not occur with the properly diluted solution.
Frequently Asked Questions About Etoposid Ebewe
Etoposid Ebewe and Vepesid both contain the same active substance, etoposide, and belong to the same drug class (topoisomerase II inhibitors). They are essentially the same medicine manufactured by different pharmaceutical companies. Etoposid Ebewe is produced by Ebewe Pharma (part of Sandoz/Novartis), while Vepesid was the original brand produced by Bristol-Myers Squibb. The therapeutic effects, side effects, and dosing are identical. Your oncologist or hospital pharmacist may use whichever brand is available, as they are pharmacologically equivalent.
The duration of etoposide treatment varies depending on the type of cancer and the specific chemotherapy regimen. For testicular cancer, treatment typically involves 3 to 4 cycles of 5 days each (BEP or EP regimen), totaling 9 to 12 weeks. For small cell lung cancer, 4 to 6 cycles are standard. Each cycle lasts 3 to 4 weeks, with etoposide given on specific days within each cycle. Your oncologist will determine the optimal number of cycles based on your response to treatment and tolerability.
Etoposide is available in oral capsule form (50 mg soft capsules). However, oral and IV formulations are not directly interchangeable. The oral bioavailability of etoposide is approximately 50% (range 25–75%), meaning only about half the dose is absorbed into the bloodstream compared to IV administration. Oral etoposide may be used in certain clinical situations, such as maintenance therapy for small cell lung cancer or in settings where IV administration is impractical. The decision to use oral versus IV etoposide is made by your oncologist based on the treatment protocol and clinical circumstances.
Yes, hair loss (alopecia) caused by etoposide is temporary. Hair typically begins to regrow within 2 to 3 months after the completion of chemotherapy. The new hair may initially have a different texture or color than before treatment, but this usually normalizes over time. Alopecia is one of the most common side effects of etoposide, affecting a significant proportion of patients. Some patients experience thinning rather than complete hair loss, depending on the dose and duration of treatment.
Blood tests are a critical part of etoposide treatment monitoring. A complete blood count (CBC) is typically performed before each treatment cycle to ensure your blood cell counts have recovered sufficiently. Additional blood tests are often performed at the expected nadir (lowest point, usually 7–14 days after treatment) to assess the degree of myelosuppression. Liver function tests and kidney function tests are also monitored regularly, especially in patients with pre-existing liver or kidney impairment. Your oncology team will establish a specific monitoring schedule based on your individual treatment plan.
Fever during etoposide treatment is a medical emergency that requires immediate attention. Because etoposide suppresses the immune system, a fever (temperature of 38°C / 100.4°F or higher) may indicate a serious infection known as febrile neutropenia. Contact your oncology team immediately or go to the emergency department without delay. Do not wait to see if the fever resolves on its own, and do not take paracetamol (acetaminophen) to lower the temperature before calling your team, as this may mask the fever. Prompt treatment with broad-spectrum antibiotics is essential and can be life-saving.
References
- European Medicines Agency (EMA). Etoposide – Summary of Product Characteristics. EMA/CHMP. Available at: www.ema.europa.eu.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List (2023). Geneva: WHO; 2023.
- Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. European Journal of Cancer. 1998;34(10):1514–1521.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer, Version 2.2025.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Testicular Seminoma and Non-Seminoma. Annals of Oncology. 2024.
- British National Formulary (BNF). Etoposide monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk.
- Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. British Journal of Haematology. 2000;109(1):13–23.
- FDA. Etoposide Prescribing Information. U.S. Food and Drug Administration. Available at: www.fda.gov.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians specializing in oncology, clinical pharmacology, and hematology. All content follows the GRADE evidence framework and is based on current international guidelines from the EMA, FDA, WHO, and peer-reviewed oncology literature.
Content Development
Written by medical professionals with expertise in oncological pharmacology and chemotherapy protocols. All medical claims are supported by Level 1A evidence from systematic reviews and international treatment guidelines.
Medical Review Process
Independently reviewed by the iMedic Medical Review Board. Content is checked against current EMA and FDA prescribing information, BNF monographs, and NCCN/ESMO clinical practice guidelines.
Last medical review: | Published:
Next scheduled review: